Back to Journals » Research and Reports in Urology » Volume 5

Procalcitonin as an indicator of urosepsis

Authors Sugimoto K, Adomi S, Koike H, Esa A

Received 12 January 2013

Accepted for publication 8 February 2013

Published 26 March 2013 Volume 2013:5 Pages 77—80

DOI https://doi.org/10.2147/RRU.S42711

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Koichi Sugimoto, Shogo Adomi, Hiroyuki Koike, Atsunobu Esa

Department of Urology, NTT West Osaka Hospital, Osaka, Japan

Background: Procalcitonin has been advocated as a marker of bacterial infection, so this study was carried out to determine the usefulness of serum procalcitonin in the early diagnosis of urosepsis.
Methods: The subjects were 37 febrile patients with urinary tract infection in whom we examined the serum procalcitonin concentration at the start of treatment.
Results: Thirty patients had acute pyelonephritis (16 simple, 14 complex), one had emphysematous pyelonephritis, five had acute prostatitis, and one had acute epididymitis. The procalcitonin level was <0.5 ng/mL in 18 patients, ≥0.5 ng/mL in one patient, ≥2 ng/mL in seven patients, and ≥10 ng/mL in 11 patients. Five of the 11 patients with procalcitonin levels ≥ 10 ng/mL had disseminated intravascular coagulation. All patients with urinary tract obstruction and disseminated intravascular coagulation had procalcitonin levels ≥ 10 ng/mL.
Conclusion: Although this retrospective study comprised a small number of patients, we found that procalcitonin was a useful marker for urinary tract infection.

Keywords: procalcitonin, urosepsis, urinary tract infection, urology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]